Cancer Blood Test Failure: Why There’s No ‘Everything’ Cancer Screen Yet

The search for a single, definitive test to detect all cancers remains elusive, despite considerable investment and hopeful marketing. The idea – a simple blood test that could screen for dozens of cancers at once – appeals to a very human desire for control and early detection. But recent trial results have underscored a critical point: finding more cancers doesn’t automatically translate to saving more lives.

This conversation unfolded for oncologist Ranjana Srivastava after an academic function, where a guest inquired about an “everything” test for cancer. The question, she notes, is a predictable one, reflecting a widespread hope for a simple solution to a complex disease. It’s a hope fueled, in part, by companies offering such tests directly to consumers, often with bold claims about their capabilities.

The Galleri Trial: A High-Profile Test Under Scrutiny

One of the most prominent examples is Galleri, a blood test developed by the American company Grail. The test aims to detect circulating tumor DNA (ctDNA) – minute fragments of cancer DNA that can be found in the bloodstream. Grail marketed Galleri as a screening tool capable of detecting signals from over 50 different types of cancer. The test, priced at $949 in the US, promises an straightforward-to-read result within two weeks: either a cancer signal detected or not. However, a positive result necessitates a battery of further tests to confirm a cancer diagnosis.

The promise of Galleri led to a large-scale trial in the UK, conducted in partnership with the National Health Service (NHS). Launched in 2021, the trial enrolled 142,000 healthy individuals aged 50-77, collecting blood samples over two years. Participants were randomly assigned to receive the Galleri test, with positive results triggering further investigation, or to continue with standard healthcare. The core question: would early detection through the blood test lead to fewer late-stage cancer diagnoses?

The results, recently published, did not meet the trial’s primary endpoint – a reduction in late-stage (stage 3 and 4) cancer diagnoses. This is a significant finding, as the primary endpoint is considered the most important measure of a clinical study’s success. As reported by the BBC, the trial’s failure to demonstrate this benefit has garnered considerable attention.

Interpreting the Results: Detection vs. Survival

Grail responded to the findings by highlighting what they termed “strong” results, including a substantial reduction in stage 4 cancer diagnoses, increased detection of stage 1 and 2 cancers, and a fourfold higher overall cancer detection rate. However, this interpretation has been met with skepticism, and the company’s share price plummeted nearly 50% following the announcement. Grail now faces investor scrutiny and a potential class action lawsuit, as reported by Business Wire.

The discrepancy between detecting more cancers and improving survival rates is a crucial point. Detecting a cancer at an earlier stage doesn’t automatically guarantee a better outcome. Some cancers detected through screening may be slow-growing and never pose a threat to the patient’s life. Intervening in these cases can lead to unnecessary treatment and anxiety, without actually extending lifespan. This is particularly relevant in older individuals, where the risks of treatment may outweigh the potential benefits.

The Nuances of Circulating Tumor DNA Testing

The concept of using circulating tumor DNA (ctDNA) for cancer detection isn’t without merit. In specific situations, ctDNA testing shows considerable promise. For example, researchers at the Walter and Eliza Hall Institute in Australia are exploring how ctDNA analysis can guide chemotherapy decisions in colon cancer patients. This involves monitoring ctDNA levels during treatment to assess response and identify potential recurrence.

However, the Galleri trial highlights the challenges of using ctDNA for broad-scale cancer screening in a healthy population. The test’s sensitivity – its ability to correctly identify those with cancer – isn’t perfect, leading to false positives that require further investigation. The test’s specificity – its ability to correctly identify those without cancer – isn’t high enough to avoid unnecessary anxiety, and procedures.

What Does This Imply for Cancer Prevention?

While a universal cancer screening test remains a distant prospect, there are well-established steps individuals can take to reduce their risk. These include reducing consumption of ultra-processed foods, moderating alcohol intake, avoiding smoking, and engaging in regular physical activity. These lifestyle modifications have a proven impact on cancer risk, supported by decades of research.

The failure of the Galleri trial serves as a reminder that cancer is a complex disease with no easy answers. While ongoing research continues to explore innovative approaches to early detection and treatment, the most effective strategies for reducing cancer risk remain those focused on prevention and healthy living. The focus should be on what we *understand* works, rather than chasing the promise of a single, elusive test.

Looking ahead, research will continue to refine ctDNA testing, focusing on specific cancer types and patient populations where it may offer the greatest benefit. Further studies are needed to determine the optimal use of these tests and to understand their potential impact on patient outcomes. The NHS trial data will be carefully analyzed to identify factors that may predict which individuals are most likely to benefit from ctDNA screening. For now, the search for a universal cancer screening test continues, but with a more realistic understanding of the challenges involved.